|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired
|
gptkb:Karyopharm_Therapeutics
|
|
gptkbp:acquisition
|
gptkb:Karyopharm_Therapeutics
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:ceo
|
gptkb:Dr._Johnson_Lau
|
|
gptkbp:clinical_trial
|
gptkb:KX2-391
Phase 1
Phase 3 trials
multiple sites
|
|
gptkbp:collaborations
|
gptkb:University_of_Buffalo
|
|
gptkbp:community_engagement
|
patient advocacy groups
|
|
gptkbp:develops
|
oral chemotherapy
|
|
gptkbp:employs
|
gptkb:scientists
|
|
gptkbp:financial_support
|
cancer patients
|
|
gptkbp:focuses_on
|
gptkb:cancer_treatment
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:founder
|
gptkb:R._Scott_Greer
|
|
gptkbp:funding
|
gptkb:venture_capital
|
|
gptkbp:grants
|
funding for studies
|
|
gptkbp:has_advisory_board
|
experts in oncology
|
|
gptkbp:has_business_development
|
strategic initiatives
|
|
gptkbp:has_clinical_data
|
patient outcomes
|
|
gptkbp:has_clinical_outcomes
|
improved survival rates
|
|
gptkbp:has_clinical_research
|
oncology drugs
|
|
gptkbp:has_collaborations_with
|
academic institutions
|
|
gptkbp:has_drug_development
|
novel therapies
|
|
gptkbp:has_drug_pipeline
|
cancer therapies
|
|
gptkbp:has_intellectual_property
|
patents
|
|
gptkbp:has_partnerships_with
|
gptkb:Celgene_Corporation
research institutions
|
|
gptkbp:has_patient_enrollment
|
clinical studies
|
|
gptkbp:has_pipeline
|
multiple oncology products
|
|
gptkbp:has_product
|
gptkb:TCR-001
|
|
gptkbp:has_product_approval
|
FDA approved drugs
|
|
gptkbp:has_product_line
|
chemotherapy agents
|
|
gptkbp:has_publications
|
gptkb:academic_journals
|
|
gptkbp:has_research_center
|
gptkb:Buffalo
|
|
gptkbp:has_research_focus
|
drug delivery systems
|
|
gptkbp:has_therapeutic_area
|
solid tumors
|
|
gptkbp:headquarters
|
gptkb:Buffalo,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Athenex Oncology
|
|
gptkbp:innovation
|
research and development
|
|
gptkbp:investment
|
biotechnology sector
|
|
gptkbp:is_a_platform_for
|
drug formulation
|
|
gptkbp:is_known_for
|
innovative cancer therapies
|
|
gptkbp:market
|
oncology landscape
|
|
gptkbp:market_position
|
global
leading biopharmaceutical company
|
|
gptkbp:marketing_strategy
|
oncology market
|
|
gptkbp:mission
|
improve patient outcomes
|
|
gptkbp:operates_in
|
gptkb:North_America
|
|
gptkbp:partnership
|
gptkb:Sorrento_Therapeutics
|
|
gptkbp:partnerships
|
pharmaceutical companies
|
|
gptkbp:patient_education
|
cancer awareness programs
|
|
gptkbp:reach
|
international markets
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
health authorities
|
|
gptkbp:team
|
experienced professionals
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.athenex.com
|
|
gptkbp:bfsParent
|
gptkb:Athenex
|
|
gptkbp:bfsLayer
|
6
|